Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
---|---|---|---|---|---|
25.06. | Enliven Therapeutics, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
20.06. | TD Cowen bekräftigt Kaufempfehlung für Enliven Therapeutics-Aktie | 1 | Investing.com Deutsch | ||
20.06. | TD Cowen reiterates buy rating on Enliven Therapeutics stock | 1 | Investing.com | ||
ENLIVEN THERAPEUTICS Aktie jetzt für 0€ handeln | |||||
16.06. | Goldman Sachs initiates Enliven Therapeutics stock with Buy rating | 1 | Investing.com | ||
13.06. | Enliven Therapeutics prices $200 million public offering | 1 | Investing.com | ||
13.06. | Enliven Therapeutics stock falls after pricing capital raise of $200M via securities offering | 1 | Seeking Alpha | ||
13.06. | Enliven Therapeutics announces $200 million public offering | 5 | Investing.com | ||
13.06. | Enliven Therapeutics, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
13.06. | Enliven Therapeutics, Inc.: Enliven Therapeutics Announces Updated Positive Data from Phase 1 Clinical Trial of ELVN-001 in CML at EHA 2025 Congress | 205 | PR Newswire | Reported cumulative MMR rate of 47% (25 of 53) by 24 weeks with 32% (13 of 41) of patients achieving MMR by 24 weeks, which continues to compare favorably to precedent... ► Artikel lesen | |
30.05. | Mizuho erhöht Kursziel für Enliven Therapeutics-Aktie auf 41 US-Dollar | 1 | Investing.com Deutsch | ||
16.05. | BTIG raises Enliven Therapeutics stock target to $45 | 1 | Investing.com | ||
15.05. | Enliven Therapeutics GAAP EPS of -$0.57 beats by $0.01 | 1 | Seeking Alpha | ||
15.05. | Enliven Therapeutics stock target raised to $40 at H.C. Wainwright | 1 | Investing.com | ||
14.05. | Enliven Therapeutics, Inc.: Enliven Therapeutics Reports First Quarter Financial Results and Provides a Business Update | 225 | PR Newswire | Updated data from the Phase 1 ENABLE clinical trial of ELVN-001 in CML to be presented at the EHA 2025 Congress in June
EHA abstract reported cumulative MMR rate... ► Artikel lesen | |
14.05. | Enliven reports positive Phase 1 trial data for ELVN-001 in CML | 1 | Investing.com | ||
14.05. | Enliven Therapeutics, Inc.: Enliven Therapeutics Announces Updated Positive Data from Phase 1 Clinical Trial of ELVN-001 in CML and Oral Presentation at the EHA 2025 Congress | 208 | PR Newswire | Reported cumulative MMR rate of 44% (16 of 36) by 24 weeks with 26% (7 of 27) of patients achieving MMR by 24 weeks, which continues to compare favorably to precedent... ► Artikel lesen | |
13.03. | Enliven Therapeutics GAAP EPS of -$0.46 | 1 | Seeking Alpha | ||
13.03. | Enliven Therapeutics, Inc. - S-8, Securities to be offered to employees in employee benefit plans | 1 | SEC Filings | ||
13.03. | Enliven Therapeutics, Inc.: Enliven Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides a Business Update | 771 | PR Newswire | Updated Phase 1 data for ELVN-001 expected mid-2025 as positive enrollment momentum continues
Expected monotherapy and combination data from the ELVN-002 Phase 1... ► Artikel lesen | |
13.03. | Enliven Therapeutics, Inc. - 10-K, Annual Report | 1 | SEC Filings |
Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
---|---|---|---|---|---|
VALNEVA | 2,690 | +3,62 % | Valneva mit Kurssprung - das ist der Grund | Die Aktie von Valneva kann zum Wochenstart kräftig zulegen. Grund für den Kurssprung sind positive Neuigkeiten von der Europäischen Arzneimittelagentur (EMA). Diese hat die im Mai verhängte Restriktion... ► Artikel lesen | |
BIOFRONTERA | 2,480 | -1,20 % | PTA-Adhoc: Biofrontera AG: Biofrontera Inc. Erfüllt die Bedingungen für die Umsetzung des Term Sheets mit der Biofrontera AG | DJ PTA-Adhoc: Biofrontera AG: Biofrontera Inc. Erfüllt die Bedingungen für die Umsetzung des Term Sheets mit der Biofrontera AG
Veröffentlichung von Insiderinformationen gemäß Artikel 17 MAR... ► Artikel lesen | |
CRISPR THERAPEUTICS | 48,600 | 0,00 % | Cathie Wood's ARK buys CRSP stock, sells ROKU and MASS | ||
AFFIMED | 0,972 | 0,00 % | XFRA DELETION OF INSTRUMENTS FROM BOERSE FRANKFURT - 28.05.2025 | The following instruments on Boerse Frankfurt do have their last trading day on 28.05.2025Die folgenden Instrumente in Boerse Frankfurt haben ihren letzten Handelstag am 28.05.2025ISIN NameBMG3728V1090 GAN... ► Artikel lesen | |
SORRENTO THERAPEUTICS | - | - | Scilex Holding Company Announces that the U.S. Bankruptcy Court has Extended the Lockup Period on Shares of Scilex Dividend Stock Previously Distributed by Sorrento to its Stockholders as a Dividend to April 14, 2025 | US Bankruptcy Court for the Southern District of Texas issued an order to extend the lock-up period on the Scilex Dividend Stock, previously distributed by Sorrento, to April 14, 2025.Accordingly... ► Artikel lesen | |
DENALI THERAPEUTICS | 12,545 | +1,01 % | DNLI's BLA for Hunter Syndrome Drug Gets FDA's Priority Review | ||
CELLECTIS | 1,806 | +37,23 % | Cellectis Reports Financial Results for the First Quarter 2025 | Lasme-cel (UCART22) Phase 1 dataset and late-stage development strategy expected in the third quarter of 2025Eti-cel (UCART20x22) Phase 1 study in relapsed or refractory B-cell non-Hodgkin lymphoma... ► Artikel lesen | |
FATE THERAPEUTICS | 0,982 | +0,20 % | Fate Therapeutics, Inc.: Fate Therapeutics Reports New Employee Inducement Awards Under Nasdaq Listing Rule 5635(c)(4) | SAN DIEGO, July 03, 2025 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to bringing a first-in-class pipeline of induced pluripotent... ► Artikel lesen | |
AGIOS | 33,400 | -0,60 % | Agios Pharmaceuticals beruft Jay Backstrom in den Verwaltungsrat | ||
VOYAGER THERAPEUTICS | 3,016 | +1,14 % | Voyager Therapeutics, Inc.: Voyager Demonstrates ALPL Receptor-Mediated Blood-Brain Barrier Transport of Novel AAV Capsids in Molecular Therapy Publication | LEXINGTON, Mass., May 15, 2025 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc. (Nasdaq: VYGR), a biotechnology company dedicated to leveraging genetics to treat neurological diseases, today announced... ► Artikel lesen | |
UNIQURE | 12,500 | +1,54 % | uniQure Inc.: uniQure Announces Appointment of Kylie O'Keefe as Chief Customer and Strategy Officer | ~ Proven biotech executive to lead commercialization of AMT-130 in Huntington's disease ~
LEXINGTON, Mass. and AMSTERDAM, June 11, 2025N.V. (NASDAQ: QURE), a leading gene therapy company advancing... ► Artikel lesen | |
ENZO BIOCHEM | 0,575 | 0,00 % | Enzo Biochem, Inc. To be Acquired by Battery Ventures in All-Cash Transaction | Transaction Follows Completion of Comprehensive Strategic Review by Special Committee of the Board to Maximize Shareholder Value Farmingdale, NY, June 24, 2025 (GLOBE NEWSWIRE) -- Enzo Biochem, Inc.... ► Artikel lesen | |
SCILEX | 6,270 | -2,03 % | Scilex Holding Company Regains Compliance with NASDAQ Minimum Bid Price Rule | PALO ALTO, Calif., April 30, 2025 (GLOBE NEWSWIRE) -- Scilex Holding Company (Nasdaq: SCLX, "Scilex" or "Company"), an innovative revenue-generating company focused on acquiring, developing and commercializing... ► Artikel lesen | |
TECTONIC THERAPEUTIC | 23,050 | +1,72 % | Tectonic Therapeutic Presents Complete Results for Positive Phase 1b Clinical Trial of TX45 in Patients with Group 2 Pulmonary Hypertension in HFpEF in Late-Breaking Presentation at ESC Heart Failure 2025 | Data confirmed TX45's tolerability profile and improvements in left ventricular function and pulmonary hemodynamics in patients with Group 2 Pulmonary Hypertension in Heart Failure with preserved... ► Artikel lesen | |
ALLOGENE THERAPEUTICS | 1,285 | +0,78 % | Allogene Therapeutics, Inc.: Allogene Therapeutics Provides Updated Phase 1 Data Highlighting Durable Responses with ALLO-316 in Heavily Pretreated Advanced Renal Cell Carcinoma at ASCO | Data Highlights Transformative Promise of CAR T in Solid TumorsPhase 1 Trial with ALLO-316 Demonstrated Potential to Provide Meaningful Clinical Benefit in Patients with CD70 TPS = 50% Advanced or... ► Artikel lesen |